The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...

Welcome to Edition 8.32 of the Rocket Report! The big news this week is NASA’s shake-up of the Artemis program. On paper, at ...

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...

Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...

A 2026 informational consumer research report examining MagnesiumFreeze (Magnesium Niacinamide Relief) topical nerve support ...

Your heartbeat isn’t just keeping you alive; it's also talking to your brain and shaping how you experience pain. Recent research shows that the ...

Peripheral artery disease (PAD) and its severe form, chronic limb-threatening ischemia (CLTI), significantly impair blood flow to the lower extremities, affecting millions of adults globally.

When an AI system in health care gives a confident answer, should clinicians trust it? In a new article from Frontiers in ...